Retinoblastoma management during the COVID-19 pandemic: A report by the Global Retinoblastoma Study Group including 194 centers from 94 countries
- 1 January 2021
- journal article
- letter
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 68 (1), e28584
- https://doi.org/10.1002/pbc.28584
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Global Retinoblastoma Presentation and Analysis by National Income LevelJAMA Oncology, 2020
- Early advice on managing children with cancer during the COVID‐19 pandemic and a call for sharing experiencesPediatric Blood & Cancer, 2020
- COVID-19: global consequences for oncologyThe Lancet Oncology, 2020
- Long-term (20-year) real-world outcomes of intravenous chemotherapy (chemoreduction) for retinoblastoma in 964 eyes of 554 patients at a single centreBritish Journal of Ophthalmology, 2020
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020
- Retinoblastoma in the United States: A 40-Year Incidence and Survival AnalysisJournal of Pediatric Ophthalmology & Strabismus, 2018
- Primary intravenous chemotherapy for group D retinoblastoma: a 13-year retrospective analysisBritish Journal of Ophthalmology, 2016
- Selective Ophthalmic Arterial Injection Therapy for Intraocular Retinoblastoma: The Long-Term PrognosisOphthalmology, 2011
- The epidemiological challenge of the most frequent eye cancer: retinoblastoma, an issue of birth and deathBritish Journal of Ophthalmology, 2009
- Retinoblastoma: treatment and survival in Great Britain 1963 to 2002British Journal of Ophthalmology, 2008